Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography

Movement Disorders

Volumn 24, Issue SUPPL. 2, 2009, Pages

  Brooks, David J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Amyloid; Dementia; Lewy body; Parkinson; PET; PIB

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BENZOTHIAZOLE DERIVATIVE; BIOLOGICAL MARKER; CARBON 11; LEVODOPA; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE; UNCLASSIFIED DRUG;

DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; LEWY BODY; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SENILE PLAQUE; UNIFIED PARKINSON DISEASE RATING SCALE;

AMYLOID; ANIMALS; BRAIN; DEMENTIA; HUMANS; LEWY BODY DISEASE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 72849109343     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22581     Document Type: Review

References (38)

1. Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000;54:1596-1602. (Pubitemid 30226802)
2. Cummings JL. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988;1:24-36. (Pubitemid 19134020)
3. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-237.
4. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921. (Pubitemid 30327112)
5. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-148. (Pubitemid 23054795)
6. Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA. Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease. Mov Disord 2003;18:81-86.
7. Jellinger KA. Prevalence of Alzheimer lesions in Parkinson's disease. Mov Disord 2003;18:1207-1208. (Pubitemid 37336952)
8. Rinne JO, Rummukainen J, Lic M, Paljarvi L, Rinne UK. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. AnnNeurol 1989;26:47-50. (Pubitemid 19190042)
9. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707. (Pubitemid 47597592)
10. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872. (Pubitemid 43970103)
11. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 2001;102:355-363. (Pubitemid 32894706)
12. Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999;53:1284-1291. (Pubitemid 29480089)
13. Mann DM, Brown SM, Owen F, Baba M, Iwatsubo T. Amyloid beta protein (A beta) deposition in dementia with Lewy bodies: predominance of A beta 42(43) and paucity of A beta 40 compared with sporadic Alzheimer's disease. Neuropathol Appl Neurobiol 1998;24:187-194. (Pubitemid 28334085)
14. Armstrong RA, Cairns NJ, Lantos PL. Beta-amyloid deposition in the temporal lobe of patients with dementia with Lewy bodies: comparison with non-demented cases and Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11:187-192. (Pubitemid 30416022)
15. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-1165.
16. Jendroska K, Lees AJ, Poewe W, Daniel SE. Amyloid beta-peptide and the dementia of Parkinson's disease. Mov Disord 1996;11:647-653. (Pubitemid 26381934)
17. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58:773-776. (Pubitemid 41552553)
18. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006;67:1931-1934. (Pubitemid 44967366)
19. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(40- methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086-2092. (Pubitemid 36368896)
20. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319. (Pubitemid 38269583)
21. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease - an [11C]PIB and [18F]FDG PET study. Neurology 2007;68:501-508. (Pubitemid 46263180)
22. Olson RE, Copeland RA, Seiffert D. Progress towards testing the amyloid hypothesis: inhibitors of APP processing. Curr Opin Drug Discov Devel 2001;4:390-401. (Pubitemid 32678528)
23. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-8855.
24. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-919. (Pubitemid 30644751)
25. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB-PET. J Neurol Neurosurg Psychiatry 2008;79:1331-1338.
26. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718-1725. (Pubitemid 46763260)
27. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528-1547.
28. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified Quantification of Pittsburgh Compound B Amyloid Imaging PET Studies: A Comparative Analysis. J Nucl Med 2005;46:1959-1972.
29. Kemppainen NM, Aalto S, Wilson IA, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006;67:1575-1580.
30. Ziolko SK, Weissfeld LA, Klunk WE, et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage 2006;33:94-102.
31. Maetzler W, Reimold M, Liepelt I, et al. [(11)C]PIB binding in Parkinson's disease dementia. Neuroimage 2008;39:1027-1033.
32. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903-910.
33. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007;64:431-434. (Pubitemid 46425701)
34. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102-112. (Pubitemid 34052562)
35. Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (Berl) 2000;100:285-290. (Pubitemid 30456155)
36. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007;27:6174-6184.
37. Fodero-Tavoletti MT, Smith DP, McLean CA, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 2007;27:10365-10371.
38. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229-234. (Pubitemid 47525398)